Will competition scrutiny change the colour of AkzoNobel and Axalta’s $25bn merger?

Akzo Nobel N.V. (Euronext Amsterdam: AKZA) and Axalta Coating Systems Ltd. (NYSE: AXTA) face a new regulatory hurdle after the United Kingdom’s Competition and Markets Authority opened an investigation into their proposed $25 billion merger. The regulator set November 11, 2026, as the deadline for its initial Phase 1 decision. It will determine whether the transaction may substantially lessen competition in a market or markets within the United Kingdom. The review can clear the deal, accept remedies or refer it for a deeper Phase 2 investigation.

The probe arrives as the companies work toward a closing targeted for late 2026 or early 2027. Their agreement would combine one of the world’s best-known decorative-paint groups with a coatings specialist that has a strong position in automotive refinish and industrial applications. The merged company is expected to have an enterprise value of approximately $25 billion and annual revenue of about $17 billion. Its scale would make it a more focused global coatings competitor, but that same scale is now the subject of formal competition analysis.

The CMA has not yet published a final theory of harm, so conclusions about required remedies would be premature. Its Phase 1 process is designed to identify whether overlaps could reduce choice, increase prices, weaken service or slow innovation for particular customer groups. Coatings are not a single uniform product: decorative paints, vehicle repair finishes, powder coatings and specialised industrial systems have different customers, specifications and distribution channels. Market definition will therefore be central to whether the combination appears concentrated in the United Kingdom.

What will the CMA examine in the AkzoNobel-Axalta merger?

The regulator will collect information from the companies, customers, distributors and competitors to understand where their activities overlap. It may examine whether professional buyers can switch suppliers easily, whether product approvals create barriers and whether national or regional distribution networks affect competition. In automotive coatings, for example, repair shops and manufacturers can require colour-matching systems, technical support and approved-product relationships that make switching more complex than comparing a tin of paint on price. The same analysis may differ for decorative or general industrial products.

The CMA will also consider whether the merged group could bundle products, use a broader distribution network to disadvantage rivals or gain bargaining power over customers. Those possibilities are questions for evidence, not established findings. Large global competitors and specialised regional suppliers may provide sufficient alternatives in some segments. In others, a narrow product definition could reveal higher combined shares and make divestments or behavioural commitments more likely.

Phase 1 reviews typically focus on whether there is a realistic prospect of a substantial lessening of competition. If concerns are identified, the parties may offer undertakings in lieu of a Phase 2 reference, often by selling an overlapping business or set of assets. A Phase 2 inquiry would extend the timetable and subject internal documents, competitive effects and efficiencies to more detailed scrutiny. That possibility creates closing risk even if the companies remain confident of eventual approval.

The United Kingdom is only one jurisdiction relevant to a cross-border coatings group. AkzoNobel and Axalta must coordinate regulatory clearances while preparing legal entities, financing and integration plans. A remedy accepted in one market can affect the synergy case globally if it removes a profitable business or customer relationship. Management will need to protect the strategic logic without allowing regulatory negotiations to erode too much of the expected value.

How is the $25 billion transaction structured?

Under the agreement announced in November 2025, AkzoNobel shareholders are expected to own 55% of the combined company and Axalta investors the remaining 45%. AkzoNobel shareholders are also due to receive a $2.5 billion special dividend. The group would initially be listed in both Amsterdam and New York before moving to a single New York Stock Exchange listing, while maintaining headquarters in Amsterdam and Philadelphia. AkzoNobel chief executive Greg Poux-Guillaume is expected to lead the combined business.

The companies project annual revenue of $17 billion, adjusted earnings before interest, tax, depreciation and amortisation of $3.3 billion and adjusted free cash flow of $1.5 billion. They are targeting $600 million of annual cost savings, with 90% expected within three years of closing. Those savings underpin a planned core profit margin of approximately 20%. The transaction values the combined business at about eight times annual earnings, according to management figures reported by Reuters.

Cost savings are expected to come from procurement, manufacturing, administration and the rationalisation of overlapping functions. Some efficiencies may be achievable without reducing customer choice, particularly in shared corporate systems or raw-material purchasing. Others could depend on consolidating sites, products or commercial teams in ways that regulators examine closely. The quality of the synergy plan will depend on how much is retained after any remedies and how quickly integration costs are absorbed.

The portfolio logic is to increase exposure to coatings, which management regards as more resilient than decorative paints during consumer downturns. Axalta brings a strong United States position and an entirely coatings-focused business, while AkzoNobel contributes global brands, industrial technologies and decorative-paint reach. The combination may also improve bargaining power with raw-material suppliers and spread research spending across a larger sales base. Its success will still depend on demand in automotive repair, new vehicle production, construction and industrial manufacturing.

Why are margins and cash flow central to the merger case?

Coatings producers have faced volatile raw-material prices, tariffs and uneven construction and industrial demand. Scale can help manage purchasing and factory utilisation, but pricing power varies by segment and customer. AkzoNobel reported second-quarter adjusted EBITDA of €398 million in July, ahead of market expectations, as price increases offset higher input costs. Its adjusted EBITDA margin improved to 15.4% from 15.0% a year earlier.

Axalta reported second-quarter net sales of approximately $1.35 billion and record quarterly adjusted EBITDA of $305 million, up 5% year on year. Its adjusted EBITDA margin increased to 22.7%, illustrating the profitability that makes the company strategically attractive to AkzoNobel. Combining Axalta’s margin profile with AkzoNobel’s broader scale is central to the promised 20% group target. Regulatory divestments that remove high-margin assets could make that target harder to reach.

Cash generation matters because integration, restructuring and shareholder distributions compete for capital. The combined group projects $1.5 billion of adjusted annual free cash flow, which could support deleveraging and investment after closing. However, synergy programmes normally require upfront spending before recurring savings appear. Investors will need a clear bridge from gross cost reductions to net cash benefits, including implementation costs, taxes and any revenue lost through remedies.

Management is relying more on self-help than on a sharp recovery in end markets. Poux-Guillaume has said the attraction lies largely in savings and portfolio quality rather than an assumption that demand will suddenly accelerate. That can make the investment case more controllable, but it also concentrates execution risk inside the integration plan. Delays, employee disruption or customer losses could weaken returns even if regulators approve the transaction.

What does the latest market reaction say about deal risk?

AkzoNobel shares closed at €56.08 on Friday, September 18, down 0.74% for the session, with a market value of approximately €9.5 billion. Axalta shares ended at $32.20, down 1.29%, valuing the company at about $6.9 billion. The modest declines after news of the UK review do not by themselves demonstrate that investors expect the transaction to fail. Phase 1 inquiries are a standard part of large cross-border mergers, though the November deadline now provides a clear regulatory catalyst.

Market scepticism has been visible since the transaction was announced. On the announcement day in November 2025, AkzoNobel recovered an earlier drop but remained broadly flat, while Axalta reversed an initial gain and traded lower. Investors were balancing the $600 million synergy target against integration complexity, execution costs and the absence of a large immediate premium for Axalta holders. The UK probe adds another variable to that original debate rather than replacing it.

The most important near-term signal will be whether the CMA clears the transaction unconditionally or identifies specific areas requiring action. A narrow remedy package could preserve most of the economics, while a Phase 2 referral would likely extend uncertainty and closing costs. Investors should also watch decisions from other competition authorities, updated synergy guidance and any change to the expected timetable. The merger can still create a global coatings leader, but regulatory approval will determine which assets, savings and customer relationships reach the finish line.